MK-677 (Ibutamoren) – Kodiac biolabs

Plain-language summaryIntrigue 72 / 100

MK-677 (Ibutamoren) is a small-molecule growth hormone releaser that mimics ghrelin. Unlike GHRPs, it is orally active because it is not a peptide. It produces sustained growth hormone elevation, increased appetite, and improved sleep, often used in research contexts as an oral GH releaser. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

48/100

Oral GH secretagogue that defines its niche but Phase 3 failure and 1990s vintage cap the ceiling

Look, MK-677 occupies a genuinely interesting position in the GH secretagogue class: it’s the compound that answered the question “can you get sustained GH elevation orally, once a day, without injections?” The answer is yes, and that answer still matters to investigators who want to study GH/IGF-1 biology in models that don’t require daily subcutaneous dosing. Merck’s program produced real clinical data: the Chapman et al. JCEM studies showed sustained IGF-1 elevation and lean body mass increases over 12 to 24 months in elderly subjects, which is a rare duration for a secretagogue trial and a genuinely useful data set.

The mechanism is well-defined: MK-677 is a high-affinity ghrelin receptor (GHS-R1a) agonist. It mimics ghrelin’s pulsatile GH secretagogue effect while bypassing the peptide limitations that make most GHRPs injection-dependent. The oral bioavailability is the real story here. Compared to ipamorelin or GHRP-6, which have essentially identical receptor pharmacology but require parenteral delivery, MK-677 lets you run longer-duration protocols without compliance issues. Thats a meaningful tool advantage that nothing else in the class currently matches.

What we don’t like: this is a 1990s Merck compound. The mechanism is single-receptor and well-understood. The Phase 3 trial in GH-deficient elderly patients was disappointing enough that the program was shelved, which is a real mark against it. The Phase 3 failure doesn’t invalidate the Phase 2 biology, but it does tell you the clinical hypothesis didn’t hold at the population level for the intended indication. The water retention and insulin resistance signal at sustained doses also complicates interpretation in any metabolic research context where you need a clean readout.

Honestly, MK-677 is more useful as a research tool than as a frontier compound. If you’re studying the GH axis, IGF-1-dependent anabolism, or ghrelin signaling and body composition, MK-677 gives you sustained once-daily GHS-R1a activation that no peptide GHRP can match practically. There’s also ongoing interest in sleep architecture effects, since GHS-R1a expression in hypothalamic circuits appears to influence slow-wave sleep independent of GH secretion. That secondary biology is arguably the fresher angle right now, though the evidence is early.

But lets be honest about the ceiling. A compound developed in the early 1990s with a well-characterized single receptor target and a failed Phase 3 is not where the frontier is. It scores in the lower established-active range: genuinely useful, real clinical data, best-in-class on oral delivery, but not a primary target for investigators chasing the next major finding in this space.

Novelty: 32
Mechanism promise: 42
In-category differentiation: 60
Evidence quality: 52
Translational signal: 48
Research bench value: 62

Rationale MK-677 is the only orally bioavailable non-peptide ghrelin receptor agonist with genuine Phase 2 clinical data, giving it real bench value for GH/IGF-1 axis research. A failed Phase 3, well-characterized single-receptor mechanism, and three decades of age keep novelty and translational scores firmly in the established range.

Orally active non-peptide ghrelin receptor agonist

A Merck-developed orally bioavailable non-peptide ghrelin receptor agonist that produces sustained GH and IGF-1 elevation with once-daily oral dosing.

Abstract

MK-677 (Ibutamoren; CAS 159752-10-0; molecular formula C27H36N4O5S; molecular weight 528.66) is a non-peptide ghrelin receptor agonist developed by Merck in the 1990s. Unlike the peptide GHRPs, MK-677 is orally bioavailable and produces sustained GH and IGF-1 elevation over 24 hours with once-daily dosing. Phase 2 trials in elderly subjects showed sustained increases in GH, IGF-1, and lean body mass over 12 to 24 month treatment periods. The compound did not advance to FDA approval; the program was deprioritized after disappointing Phase 3 results in the GHD elderly population. The compound is sold as a research chemical/dietary supplement in some markets, though FDA has issued warnings against its sale as a supplement. Pharmacokinetics: plasma half-life 4 to 6 hours; high oral bioavailability; hepatic CYP3A4 metabolism. Doses are typically 10 to 25 mg orally once daily, usually at bedtime to align with the natural GH pulse. Adverse events include increased appetite, water retention, and modest insulin resistance with chronic high-dose use.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-078Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.